Payment overview · 2025
General Payments
$915.99
62 reported records · 15 companies
Healthcare provider profile · identity verified
Wesley A Klir, MD
Allopathic & Osteopathic Physicians|Family Medicine · KALIDA, OH · NPI 1902883234
Verified facts
What the public records show
CMS Open Payments records show Wesley A Klir, MD received $915.99 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Qulipta, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 382 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.21 | 22.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.39 | 18.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $141.05 | 15.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.93 | 8.9% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $60.95 | 6.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.24 | 4.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.23 | 3.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.59 | 3.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.59 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.72 | 3.1% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.99 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.90 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.61 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.01 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.58 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $915.99 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.74 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $141.05 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.11 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.98 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.46 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $60.95 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.47 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.47 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.69 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.11 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 72 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
382 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1245 | 276 |
| Losartan Potassium | Losartan Potassium | 1060 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 978 | 185 |
| Pantoprazole Sodium | Pantoprazole Sodium | 858 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 853 | 170 |
| Potassium Chloride | Potassium Chloride | 727 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 678 | 157 |
| Bumetanide | Bumetanide | 500 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 463 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 434 | 86 |
| Lisinopril | Lisinopril | 406 | 96 |
| Eliquis | Apixaban | 382 | 65 |
| Prednisone | Prednisone | 382 | 252 |
| Clopidogrel | Clopidogrel Bisulfate | 376 | 66 |
| Trazodone Hcl | Trazodone Hcl | 369 | 60 |
| Omeprazole | Omeprazole | 364 | 91 |
| Metformin Hcl | Metformin Hcl | 355 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 350 | 94 |
| Alprazolam | Alprazolam | 343 | 70 |
| Sertraline Hcl | Sertraline Hcl | 338 | 52 |
| Meloxicam | Meloxicam | 337 | 128 |
| Donepezil Hcl | Donepezil Hcl | 323 | 52 |
| Tramadol Hcl | Tramadol Hcl | 313 | 73 |
| Furosemide | Furosemide | 304 | 55 |
| Simvastatin | Simvastatin | 301 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 60 |
| Gabapentin | Gabapentin | 275 | 66 |
| Allopurinol | Allopurinol | 268 | 57 |
| Clonidine Hcl | Clonidine Hcl | 246 | 49 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 240 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 204 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 186 | 33 |
| Sucralfate | Sucralfate | 186 | 30 |
| Warfarin Sodium | Warfarin Sodium | 185 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 183 | 33 |
| Mirtazapine | Mirtazapine | 178 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 43 |
| Carvedilol | Carvedilol | 171 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 167 | 29 |
| Lorazepam | Lorazepam | 166 | 38 |
| Spironolactone | Spironolactone | 164 | 40 |
| Famotidine | Famotidine | 163 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 25 |
| Lactulose | Lactulose | 157 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 70 |
| Azithromycin | Azithromycin | 152 | 118 |
| Levetiracetam | Levetiracetam | 152 | 20 |
| Divalproex Sodium | Divalproex Sodium | 149 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 147 | 31 |
| Memantine Hcl | Memantine Hcl | 133 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 23 |
| Januvia | Sitagliptin Phosphate | 129 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 126 | 28 |
| Finasteride | Finasteride | 125 | 34 |
| Jardiance | Empagliflozin | 122 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 113 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 111 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 17 |
| Metformin Hcl Er | Metformin Hcl | 108 | 28 |
| Levofloxacin | Levofloxacin | 105 | 89 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 17 |
| Bupropion Xl | Bupropion Hcl | 103 | 19 |
| Fenofibrate | Fenofibrate | 101 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 19 |
| Montelukast Sodium | Montelukast Sodium | 98 | 25 |
| Atenolol | Atenolol | 96 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 95 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 14 |
| Pregabalin | Pregabalin | 91 | 22 |
| Myrbetriq | Mirabegron | 89 | 16 |
| Buspirone Hcl | Buspirone Hcl | 88 | 20 |
| Loperamide | Loperamide Hcl | 86 | 33 |
| Glipizide | Glipizide | 81 | 21 |
| Clonazepam | Clonazepam | 80 | 15 |
| Ozempic | Semaglutide | 80 | 16 |
| Baclofen | Baclofen | 78 | suppressed |
| Cefdinir | Cefdinir | 78 | 68 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 19 |
| Trulicity | Dulaglutide | 74 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 72 | 20 |
| Midodrine Hcl | Midodrine Hcl | 72 | 18 |
| Rybelsus | Semaglutide | 72 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 13 |
| Xarelto | Rivaroxaban | 71 | 14 |
| Synthroid | Levothyroxine Sodium | 70 | 21 |
| Valsartan | Valsartan | 70 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 65 | 14 |
| Ondansetron Odt | Ondansetron | 63 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 46 |
| Ezetimibe | Ezetimibe | 59 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 11 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Diazepam | Diazepam | 53 | suppressed |
| Cefadroxil | Cefadroxil | 52 | 40 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Metolazone | Metolazone | 52 | suppressed |
| Glimepiride | Glimepiride | 51 | 14 |
| Glipizide Er | Glipizide | 50 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Memantine Hcl Er | Memantine Hcl | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 38 |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | 11 |
| Nystatin | Nystatin | 45 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Gemtesa | Vibegron | 43 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | 17 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 18 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 38 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 21 |
| Amoxicillin | Amoxicillin | 34 | 13 |
| Fluconazole | Fluconazole | 34 | 25 |
| Nuplazid | Pimavanserin Tartrate | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Nitroglycerin | Nitroglycerin | 33 | 23 |
| Nyamyc | Nystatin | 33 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Digoxin | Digoxin | 31 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 14 |
| Cefuroxime | Cefuroxime Axetil | 30 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 15 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Nystop | Nystatin | 22 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Cefprozil | Cefprozil | 20 | 18 |
| Febuxostat | Febuxostat | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | 12 |
| Mirabegron Er | Mirabegron | 18 | 11 |
| Novolog | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 16 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Torsemide | Torsemide | 16 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Etodolac Er | Etodolac | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $915.99 · 62 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BEYFORTUS, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, ENTRESTO, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, GEMTESA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, ROTATEQ, Rybelsus, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error